Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
Hallmark Moments... Writing the perfect greeting card is never easy. Wording needs to be precise. The length so exact. Find all those details you definitely want to include... or leave out. While still managing to strike just the proper tone. Nothing too dark and serious, but also not too ...
There were whispers in the marketplace that Bristol Myers-Squibb (NYSE: BMY ) was still looking to beef up their pipeline in NASH but Dealreporter broke the news that the BMY’s business development chief Paul Biondi is “actively looking for acquisition or license opportunities ...
Education is the most powerful weapon which you can use to change the world -Nelson Mandela Investment Analysis : The scientific development and approval of Obeticholic acid (OCA; Ocaliva ) therapy developed by Intercept (ICPT) Pharmaceuticals for Primary Biliary Cholangitis ((PBC...
Money flow has perked up in certain NASH players after Galmed Pharmaceuticals ( GLMD +183.4% ) reported positive results on Aramchol this morning. More news on: Galmed Pharmaceuticals Ltd., CymaBay Therapeutics, Intercept Pharmaceuticals, Healthcare stocks news, Stocks on the move, R...
Recently, Madrigal Pharmaceuticals ( MDGL ) announced that it had met both liver biopsy based endpoints for its phase 2 non-alcoholic steatohepatitis ((NASH)) study. This opens up the opportunity for the company to move on to a phase 3 study with more patients to confirm its findings. Se...
There can be no greater gift than that of giving one’s time and energy to help others without expecting anything in return. —Nelson Mandela Novartis AG (NVS) is a Swiss (Basel, Switzerland) multibillion biopharmaceutical company with a market cap of $178B and a broad the...
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf...
I never lose. I either win or learn. —Nelson Mandela Gilead Sciences (GILD) is a multibillion ($89B market cap) biopharmaceutical company that has and is still revolutionizing the infectious disease market with innovative anti-viral therapies for HIV/AIDS, Hep B and C. It seem...
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Recently, Conatus Pharmaceuticals (CNAT) announced results for its phase 2b POLT-HCV-SVR study. What I must say about these results after having looked at them is that they were in the middle in terms of efficacy. The middle being that they weren't a complete failure or a complete success ov...
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...